



Thursday 8th February, 2007
(13.30 - 18.15)

13.40 - 14.30 Keynote Lecture

From Bench to bedside: predicting the bacterial response to chemotherapy

D. Low (Canada)

14.30 - 18.15 Symposium 1:

Challenges in hospital infection I: changing targets and environments

- What is the point of PK/PD modelling?
A. MacGowan (United Kingdom)
- What are the challenges of bacterial eradication?
K. Klugman (USA)
- Panel: how should clinicians evaluate pre-clinical data?
J. Blondeau (Canada)
- Treating a moving target
M. Wilcox (United Kingdom)
- Round table:
 - Different patients, different needs: changing patient profiles
 - Country experience of changing hospital environment*M. Miravittles (Spain)*



Friday 9th February, 2007
(08.30 - 19.00)

08.30 - 12.00 Symposium 2:

Challenges in hospital infection II: the role of fluoroquinolones?

- Fluoroquinolone efficacy in CAP - the evidence?
M. Niederman (USA)
- Fluoroquinolone efficacy in AECB - the evidence?
A. Anzueto (USA)
- Clinical perspectives on fluoroquinolone therapy
E. Goldstein (USA)
- A role for fluoroquinolones in the current hospital setting?
E. Rubinstein (Canada)
- Can fluoroquinolones meet the challenges in the modern hospital environment?
R. Grossman (USA)

12.00 - 13.30 *Lunch break*



Friday 9th February, 2007
(08.30 - 19.00)

13.30 Introduction to RTI4: Chairmen

13.40 - 14.30 The BSAC Lecture:

Avian influenza 2007: residual threat or impending reality

K. Nicholson (United Kingdom)

14.30 - 16.00 Symposium 3:

HealthCare Associated Pneumonia (HCAP): a new therapeutic paradigm

- What is HealthCare Associated Pneumonia?
J. Carratala (Spain)
- The common HCAP pathogens
C. Luna (Argentina)
- Therapy of HealthCare Associated Pneumonia
M. Niederman (USA)

16.00 - 16.30 *Tea break*

16.30 - 17.00 Plenary 1:

Epidemiological consequences of pneumococcal vaccination

K. Klugman (USA)

17.00 - 17.45 Plenary 2:

RTI Guidelines: issues in AECB / COPD and bronchiectasis


R. Wilson (United Kingdom)

17.45 - 18.15 Special Session:

The future regulatory environment for antibiotic development in RTI: superiority/placebo studies

G. Tillotson (USA)

18.15 - 19.30 *Welcome cocktail reception*



Saturday 10th February, 2007 (08.30 - 18.00)

08.30 - 09.00 Plenary 3:
Patient reported outcomes (PRO) in AECB
S. Sethi (USA)

- 09.00 - 10.30** Symposium 4:
COPD-AECB and related conditions
- What antimicrobial therapy for mild-to-moderate AECB?
A. Anzueto (USA)
 - Prophylaxis of AECB by antibiotic therapy
N. Hoiby (Denmark)
 - Bronchiectasis in COPD: diagnosis and management
R. Wilson (United Kingdom)
 - The role of *Pseudomonas aeruginosa* in late COPD
E. Monso (Spain)

10.30 - 11.00 *Coffee break*

- 11.00 - 13.00** Symposium 5:
Issues in Gram-positive pneumonia
- The role of community-acquired MRSA in CAP
D. Nathwani (United Kingdom)
 - Treatment challenges in MRSA infections
T. Welte (Germany)
 - Gram-positive pneumonias: the current new drugs
H. Lode (Germany)
 - Drugs in development: potential roles
A. Torres (Spain)

13.00 - 14.00 *Lunch break*



Saturday 10th February, 2007

14.00 - 14.30 Plenary 4:

Requirement for hospital admission in CAP:

what is the most accurate prediction rule?

S. Ewig (Germany)

14.30 - 16.30 Symposium 6:

Nosocomial and ICU pneumonia

- Improved diagnosis for improved outcomes
J.Y. Fagon (France)
- Pulmonary infections in haematological disease
C. Agusti (Spain)
- Aspiration pneumonia and lung abscess
H. Lode (Germany)
- De-escalation therapy
J. Rello (Spain)

16.30 - 17.00 *Tea break*

17.00 - 17.30 Plenary 5:

Steroid treatment of severe CAP

A. Torres (Spain)

17.30 - 18.00 Plenary 6:

RTI Guidelines: issues in pneumonias

M. Woodhead (United Kingdom)



Sunday 11th February, 2007 (08.30 - 13.00)

08.30 - 10.30 Symposium 7:

Community acquired pneumonia

- Pharmacodynamic assessment of drugs for CAP
A. MacGowan (United Kingdom)
- The role of new penems
E. Rubinstein (Canada)
- The role of new cepheims
J. Garau (Spain)
- The German CAP-NET database on CAP
T. Welte (Germany)
- New concepts on non-responding CAP and stability
R. Menendez (Spain)
- Patient compliance and optimized outcomes
G. Huchon (France)

10.30 - 11.00 Plenary 7:

Risk factors for development of resistance in *Streptococcus pneumoniae*: the Belgian experience

J. van Eldere (Belgium)



Sunday 11th February, 2007

11.00 - 13.00 Round Table:

The threatened demise of antibiotics in RTI: utility to futility in a single century

- Has resistance peaked in RTI pathogens
 - drivers of resistance
D. Low (Canada)
- Linking antibiotic use to bacterial resistance
P. Ball (United Kingdom)
- The impact and dangers of reduced antibiotic use
R. Wise (United Kingdom)
- Plans for action: planning and implementation
 - Initiatives in use-reduction:
 - Europe Overview
J. Garau (Spain)
 - Turkey
S. Unal (Turkey)
 - Malaysia
V. Lim (Malaysia)
- Will new antibiotics assist resistance control
F. Scaglione (Italy)

13.00 *Close of meeting*

A commercial exhibition and poster sessions will be open throughout the Forum. Registration for the Thursday and Friday (morning) sessions will be available from 11.00 on Thursday, 08 February, 2007.

Registration for individual attending only the Friday to Sunday sessions will be available from 11.00 on Friday, 09 February, 2007 (group registrations from 09.00 - 11.00)

The traditional Welcome Cocktail reception will be held following the Friday afternoon scientific sessions.